ear nose throat News
-
Intersect ENT to Participate at the Oppenheimer 31st Annual Healthcare Conference
Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that Tom West, President & Chief Executive Officer, and Randy Meier, Executive Vice President & Chief Financial Officer, will participate in a fireside chat at the Oppenheimer 31st Annual Healthcare Conference. The fireside ...
-
Understanding the Difference between COVID-19 Symptoms and Sinus Disease World Sinus Health Awareness Day 2021
The American Academy of Otolaryngology–Head and Neck Surgery (AAO-HNS), in partnership with Intersect ENT, Inc., launched a public education campaign that provides clinically-developed information by experts in the field aimed at helping people better understand their nasal and sinus symptoms. World Sinus Health Awareness Day, with its inaugural celebration on September 29, has an ...
-
Lyra Therapeutics to Highlight LYR-210 and LYR-220 Clinical Programs at Virtual Event with Leading Clinical CRS Experts
Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues will host a virtual event with leading chronic rhinosinusitis (CRS) experts to highlight the Company's LYR-210 and LYR-220 clinical ...
-
Optim Partners with MedShare to donate ENTity Endoscopes
Optim LLC, a premier manufacturer of proprietary flexible endoscopes for use in the visual diagnosis of Ear-Nose-and-Throat (“ENT”) disorders, announced today it has partnered with MedShare of Decatur, GA to donate the companies ENTity Nasopharyngoscopes to under-served communities around the globe. “The opportunity to give back to communities who do not have access to ...
By Optim LLC
-
Lyra Therapeutics to Present at Upcoming Virtual Investor Conferences
Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues, today announced that Maria Palasis, Ph.D., Lyra's President and Chief Executive Officer, will present in a virtual format at three ...
-
Lyra Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues, today announced that Maria Palasis, Ph.D., Lyra’s President and Chief Executive Officer, will present in a virtual format at the ...
-
Lyra Therapeutics To Present Lantern Phase 2 Study Results For Lyr 210 In Oral Presentation At Cosm 2021 Virtual
Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat (ENT) diseases, today announced that the company will present Phase 2 results from the LANTERN study for LYR-210, the company’s lead product candidate ...
-
FDA approves first artificial iris
The U.S. Food and Drug Administration has announced its approval of the first stand-alone prosthetic iris in the United States that could help patients with certain types of eye damage see clearly and improve their appearance. The surgically implanted device, called the CustomFlex Artificial Iris, is meant to treat adults and children whose iris — the part of the eye that is colored around ...
-
Dalent Medical Secures $1.5 Million Round, Granted Patent Protecting New Medical Device for ENT Physicians
Dalent Medical, a Miami-based company developing innovative devices for Ear, Nose & Throat doctors is pleased to announce the closing of a $1.5 million funding round. The company has raised over $2 million from private investors since 2018. The additional funds will be used to produce inventory and ramp up sales & marketing to support the rollout of the company’s first patented ...
-
Optim LLC awarded Defense Logistics Agency (DLA) Capital (ECAT) Contract
Optim LLC, a premier manufacturer of proprietary flexible endoscopes for use in the visual diagnosis of Ear-Nose-and-Throat (“ENT”) disorders, announced today the company received an ECAT (electronic catalog) contract from the Defense Logistics Agency valued at up to $18,750,000 over 5 years. DLA Troop Support’s Medical supply chain developed ECAT to streamline its business ...
By Optim LLC
-
Sinusleeve™ Balloon Device Completes FDA Listing, Dalent Medical Begins Sales in South Florida
Dalent Medical, a Miami-based company developing innovative devices for Ear, Nose & Throat Doctors is pleased to announce that the Sinusleeve™ Balloon Sinus Dilation Sleeve has completed the United States Food and Drug Administration’s listing process. The company will begin selling the Sinusleeve™ balloon device in their home state of Florida to Otolaryngologists ...
-
Lyra Therapeutics to Host Virtual Chronic Rhinosinusitis KOL Event on August 31
Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues will host Chronic Rhinosinusitis (CRS) Key Opinion Leader Event on Tuesday, August 31, 2021 from 3:00 p.m. - 4:30 p.m. ET. Robert Kern, ...
-
Intersect ENT Announces Launch of the New Straight Delivery System Packaged with the PROPEL Mini Sinus Implant
Intersect ENT®, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced the U.S. availability of the new Straight Delivery System (“SDS”) packaged with the company’s PROPEL® Mini (mometasone furoate) Sinus Implant. The combined packaging of the SDS with PROPEL Mini received ...
-
Lyra Therapeutics Announces Four Abstracts Selected for Presentations at Upcoming ERS and ARS Meetings, Including New LANTERN 6-Month Follow-Up and Pharmacokinetic Data
Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues, today announced that four abstracts highlighting LYR-210 results in chronic rhinosinusitis and the XTreo™ platform have been ...
-
Optim LLC celebrates 50 Year Anniversary of Optical Imaging Excellence
Optim LLC, a leading manufacturer of proprietary portable flexible endoscopes and videoscopes for use in the visual diagnosis of Ear-Nose-and-Throat (“ENT”) disorders, contraband detection equipment as well as components for the Ultrasound market, announced today the company is celebrating a major milestone with 50 years in the optical imaging industry. Originally founded in 1970 as ...
By Optim LLC
-
Medtronic to Acquire Intersect ENT
Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced that it has entered into a definitive agreement with Intersect ENT (NASDAQ: XENT), a global ear, nose, and throat (ENT) medical technology leader dedicated to transforming patient care, in which Medtronic will acquire all outstanding shares of Intersect ENT for $28.25 per share in an all-cash transaction implying ...
-
Expand Post-Market Study Evaluating Longer-Term Outcomes of PROPEL Contour Sinus Implant in the Frontal Sinus Ostia Following In-Office Balloon Sinus Dilation
Intersect ENT®, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that it began the process of initiating the Company’s EXPAND Clinical Study by successfully registering on ClinicalTrials.gov (NCT04858802). EXPAND is a prospective, randomized, single-blind, intra-patient controlled, ...
-
Lyra Therapeutics Announces Publication of Preclinical Pharmacokinetics and Drug Release characterization for XTreo™ Technology Platform in the American Journal of Rhinology & Allergy
Outcomes supported advancing into clinical development for LYRA’s first indication, Chronic Rhinosinusitis, with lead product candidate, LYR-210, currently poised to enter Phase 3 studies Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, ...
-
Lyra Therapeutics Provides Corporate Update and Anticipated Milestones for 2021
Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat (ENT) diseases, today provided a corporate update and anticipated milestones for 2021. Corporate Update & Anticipated Milestones for 2021 LYR-210: ...
-
First Implants of PROPEL Contour in Patients with Chronic Rhinosinusitis Following Frontal Sinus Surgery in Europe
Intersect ENT®, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that Helios Dr. Horst Schmidt Kliniken Wiesbaden in Germany was the first hospital outside the United States to offer the Company’s PROPEL® Contour (mometasone furoate) sinus implant following functional endoscopic ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you